BeOne Medicines Ltd. (ONC) Stock Price & How to Invest

BeOne Medicines is a global oncology company built around one large drug. BRUKINSA (zanubrutinib), a BTK inhibitor used in chronic lymphocytic leukemia and other B-cell cancers, produced ~$1.2 billion of the ~$1.68 billion in product revenue it booked in the second quarter of 2026. Around it sit TEVIMBRA (tislelizumab), a PD-1 antibody; BEQALZI (sonrotoclax), a BCL2 inhibitor that won U.S. accelerated approval in relapsed or refractory mantle cell lymphoma; ZIIHERA (zanidatamab) in HER2-positive gastroesophageal cancer; and in-licensed Amgen products sold in China. The company was BeiGene until recently. Its Nasdaq listing began trading under symbol ONC instead of BGNE on January 2, 2025, and effective May 27, 2025 the company moved its jurisdiction of incorporation from the Cayman Islands to Switzerland and took the BeOne Medicines name. What a U.S. holder actually owns is an American Depositary Share representing 13 ordinary shares, the same shares listed in Hong Kong (06160) and, as RMB shares, on Shanghai's STAR Market (688235).

The investment picture is a biotech that has finished crossing into profit. Trailing twelve-month revenue of ~$6.13 billion came with ~$656 million of GAAP net income after years of losses, and management raised 2026 revenue guidance to $6.6 billion to $6.8 billion with GAAP operating income of $1.0 billion to $1.1 billion. Second-quarter gross margin reached 90% of product sales, free cash flow was ~$435 million, and the balance sheet holds ~$5.28 billion of cash against ~$1.07 billion of debt. The argument is over what that stream is worth at roughly 6.8 times trailing sales and about 64 times trailing GAAP earnings. Supporters cite BRUKINSA taking share from Imbruvica and Calquence, a revenue base now ~54% U.S. and only ~30% China, and a deep internally discovered pipeline. Skeptics cite dependence on a single molecule, an AbbVie trade secret suit that survived dismissal, and a company whose research, manufacturing and selling straddle two governments rewriting the rules on each other.

Concentration is the central issue: BRUKINSA is roughly 70% of product revenue, so any label setback, reimbursement change or successful patent challenge lands directly on the whole business. Zydus filed an ANDA with Paragraph IV certifications against certain BRUKINSA Orange Book patents in early 2026, though it has not challenged the composition of matter patent that runs to 2034. AbbVie's trade secret complaint over the BTK degrader program, including tacabrutideg, survived a motion to dismiss on May 12, 2026 and remains pending with no trial date. About 30% of revenue and a large share of manufacturing and clinical operations sit in China, leaving the company exposed to tariffs, trade-status changes and U.S. or Chinese action against firms with large operations in both. The valuation, near 64 times trailing GAAP earnings on a profit record barely a year old, assumes the growth and the margin improvement both continue.

27 analysts publish price targets on ONC, averaging $433.02 against a $369.15 price as of August 2026, or +17.3%. The published targets run from $370.00 to $528.00, a moderate spread, and the ratings split 27 buy, 0 hold, 0 sell. Over the last six months there have been 9 raises and 2 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full ONC forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on BeOne Medicines Ltd.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. BRUKINSA taking share in B-cell cancers. BRUKINSA global sales reached ~$1.2 billion in the second quarter of 2026, up 31% year over year, with U.S. The most optimistic published target, $528.00, assumes this works close to its best case.

The case against. Concentration is the central issue: BRUKINSA is roughly 70% of product revenue, so any label setback, reimbursement change or successful patent challenge lands directly on the whole business. The most pessimistic target, $370.00, is roughly what ONC is worth if this bites instead.

Read the full bull and bear case on ONC, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see BeOne Medicines Ltd.'s investor relations page or your broker.

• Revenue (TTM): ~$6.13B
• Q2 2026 revenue: ~$1.71B, up ~30% year over year
• GAAP net income (TTM): ~$656M (FY2025 was ~$287M, FY2024 a ~$645M loss)
• Q2 2026 diluted EPS per ADS: ~$2.05 GAAP, ~$3.84 adjusted
• Market cap: ~$42B (~113.7M ADSs, about 1.48B ordinary shares)
• Valuation: ~6.8x trailing sales, ~64x trailing GAAP earnings

Figures come from the Form 10-Q for the quarter ended June 30, 2026 and the accompanying Q2 2026 earnings release filed with the SEC on August 5, 2026. The company reports in U.S. dollars, so no conversion is involved despite the Swiss domicile and the Hong Kong and Shanghai listings. Note that per-ADS figures are 13 times the per-ordinary-share figures, which is why a screener showing EPS of $0.16 and one showing $2.12 can both be right.

Other names that sit close to ONC: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get ONC exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so ONC sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where ONC fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

A newly profitable oncology company growing ~30% on the strength of one dominant BTK inhibitor, priced at roughly 6.8 times sales while carrying real single-product and U.S.-China policy exposure.

Whether ONC is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ONC a buy or a sell?, and where the stock could go from here in the ONC stock forecast.

For income investors, whether ONC pays a dividend and how the payout looks is covered in does ONC pay a dividend? And to weigh ONC against a peer, read the full side-by-side comparisons: ONC vs ABBV and ONC vs JNJ.